Logo image of NANO.PA

NANOBIOTIX (NANO.PA) Stock Price, Forecast & Analysis

Europe - Euronext Paris - EPA:NANO - FR0011341205 - Common Stock

18.24 EUR
+0.14 (+0.77%)
Last: 1/14/2026, 7:00:00 PM

NANO.PA Key Statistics, Chart & Performance

Key Statistics
Market Cap879.45M
Revenue(TTM)-14.04M
Net Income(TTM)-51.64M
Shares48.22M
Float40.80M
52 Week High25.5
52 Week Low2.62
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-1.09
PEN/A
Fwd PEN/A
Earnings (Next)03-31
IPO2012-10-29
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
NANO.PA short term performance overview.The bars show the price performance of NANO.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 100 200 300

NANO.PA long term performance overview.The bars show the price performance of NANO.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years 100 200 300 400

The current stock price of NANO.PA is 18.24 EUR. In the past month the price decreased by -6.47%. In the past year, price increased by 499.87%.

NANOBIOTIX / NANO Daily stock chart

NANO.PA Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to NANO.PA. When comparing the yearly performance of all stocks, NANO.PA is one of the better performing stocks in the market, outperforming 99.46% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

NANO.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to NANO.PA. NANO.PA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

NANO.PA Financial Highlights

Over the last trailing twelve months NANO.PA reported a non-GAAP Earnings per Share(EPS) of -1.09. The EPS decreased by -47.3% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -114.32%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%76.09%
Sales Q2Q%186.77%
EPS 1Y (TTM)-47.3%
Revenue 1Y (TTM)-138.77%

NANO.PA Forecast & Estimates

12 analysts have analysed NANO.PA and the average price target is 21.95 EUR. This implies a price increase of 20.32% is expected in the next year compared to the current price of 18.24.

For the next year, analysts expect an EPS growth of 55.91% and a revenue growth 24.15% for NANO.PA


Analysts
Analysts86.67
Price Target21.95 (20.34%)
EPS Next Y55.91%
Revenue Next Year24.15%

NANO.PA Ownership

Ownership
Inst Owners28.98%
Ins Owners0.63%
Short Float %N/A
Short RatioN/A

About NANO.PA

Company Profile

NANO logo image Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.

Company Info

NANOBIOTIX

60 rue de Wattignies

Paris ILE-DE-FRANCE FR

Employees: 108

NANO Company Website

NANO Investor Relations

Phone: 33140260470

NANOBIOTIX / NANO.PA FAQ

What does NANO do?

Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. The company is headquartered in Paris, Ile-De-France and currently employs 103 full-time employees. The company went IPO on 2012-10-29. The firm designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. The company develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The firm's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.


What is the current price of NANO stock?

The current stock price of NANO.PA is 18.24 EUR. The price increased by 0.77% in the last trading session.


Does NANO stock pay dividends?

NANO.PA does not pay a dividend.


What is the ChartMill rating of NANOBIOTIX stock?

NANO.PA has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


On which exchange is NANO.PA stock listed?

NANO.PA stock is listed on the Euronext Paris exchange.


What is the expected growth for NANO stock?

The Revenue of NANOBIOTIX (NANO.PA) is expected to grow by 24.15% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.


Can you provide the number of employees for NANOBIOTIX?

NANOBIOTIX (NANO.PA) currently has 108 employees.